Our findings have important therapeutic implications—in usual practice for T2D patients, strategies for minimizing the risks of CVDs and hospitalized hypoglycemia should be aware and optimized for the use of a basal insulin with IAHI versus LAIA, while IAHI may be associated with a lower risk of MVDs. The gene discussed is INS; the disease is Hypoglycemia.